Goldman Sachs Added Amgen (AMGN) to its Conviction Buy List
More News related to AMGN
- Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
- 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
- Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
- Bernstein Upgrades Amgen (AMGN) to Outperform
- Amgen (AMGN) October volatility flat at 44 into FDA action
Goldman Sachs added Amgen Inc. (Nasdaq: AMGN) to its Conviction Buy List.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Related Categories
Analyst CommentsStocks Mentioned
-1.29Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
